Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epidermal growth factor inhibition in solid tumours.

Apar Kishor Ganti1, Anil Potti

  • 1Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA. aganti@unmc.edu

Expert Opinion on Biological Therapy
|August 27, 2005
PubMed
Summary

Epidermal growth factor receptor (EGFR) is a key target in cancer therapy. Approved treatments include EGFR antibodies and tyrosine kinase inhibitors, with ongoing development of new agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors.

Clinical lung cancer·2026
Same author

Perceived Barriers and Facilitators to Physical Activity Engagement Among Cancer Survivors: A Qualitative Study.

Cancers·2026
Same author

Ixazomib triggers autophagic degradation of MUC5AC/integrin-β4 and inhibits non-small cell lung cancer progression.

Cancer letters·2026
Same author

NR4A2 induces perineural invasion in head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma via CXCL5/CXCR2 signaling axis.

Cancer letters·2026
Same author

Programmed death-ligand 1 expression is associated with local invasion and distant metastases in differentiated thyroid cancer: Systematic review and meta-analysis.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research·2026
Same author

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1-Positive Metastatic NSCLC.

Oncology (Williston Park, N.Y.)·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The epidermal growth factor receptor (EGFR) is implicated in the development of numerous human cancers.
  • Targeting EGFR offers a promising strategy for anticancer therapy.

Purpose of the Study:

  • To review currently approved therapies targeting EGFR.
  • To present efficacy data for these agents in various human malignancies.
  • To mention emerging EGFR-targeting agents in early development.

Main Methods:

  • Review of approved EGFR-targeting agents: cetuximab (monoclonal antibody), gefitinib, and erlotinib (tyrosine kinase inhibitors).
  • Presentation of clinical efficacy data for these agents across different malignancies.
  • Inclusion of information on novel agents in early developmental stages.

Related Experiment Videos

Main Results:

  • Cetuximab, gefitinib, and erlotinib are established EGFR-targeting therapies.
  • Efficacy data demonstrates the clinical utility of these agents in treating various cancers.
  • Several new EGFR-targeting agents are under investigation.

Conclusions:

  • EGFR-targeting therapies, including antibodies and tyrosine kinase inhibitors, are crucial in oncology.
  • Approved agents like cetuximab, gefitinib, and erlotinib show clinical efficacy.
  • Ongoing research into novel agents promises further advancements in EGFR-targeted cancer treatment.